InfuSystem Holdings, Inc 8-K

What Happened InfuSystem Holdings, Inc. announced that its Audit Committee approved on March 13, 2026 the dismissal of Deloitte & Touche LLP as the company’s independent registered public accounting firm and the appointment of Grant Thornton LLP to serve as auditor for the fiscal year ending December 31, 2026. Grant Thornton will audit the consolidated financial statements for FY2026, review the quarterly statements for the first three quarters of 2026, and audit the company’s internal control over financial reporting as of December 31, 2026. The company disclosed that neither it nor anyone on its behalf consulted Grant Thornton on accounting or auditing matters prior to the appointment.

Key Details

• Date of committee action: March 13, 2026.
• New auditor: Grant Thornton LLP for audits and quarterly reviews in 2026.
• Prior auditor: Deloitte & Touche LLP (auditor for fiscal years ended Dec 31, 2025 and 2024). Deloitte’s audit reports for 2025 and 2024 contained no adverse opinions or qualifications.
• No disagreements or reportable events were reported with Deloitte for 2024–2025 or through March 13, 2026; Deloitte provided a letter dated March 19, 2026, responding to the 8‑K disclosures.

Why It Matters A change in independent auditor is a notable governance event that can affect investor perception of financial reporting and controls. InfuSystem has a clean disclosure that there were no disagreements or reportable events with Deloitte, and the company has chosen Grant Thornton to perform its 2026 audits and quarterly reviews, including an audit of internal control over financial reporting. Investors should note the timing (appointment for FY2026) and watch for any future commentary in quarterly or annual filings about the transition and audit results.